S-TARget therapeutics is a biotech start-up company founded in September 2010, that develops novel therapeutic vaccines to cure and prevent allergic diseases. S-TARget‘s vaccines are based on a unique, proprietary technology platform that addresses the cause of the disease not only the symptoms. They are directed against major, widespread allergic diseases that currently cannot be cured – including severe forms of allergy.

Lead candidate SG100 targets allergic asthma induced by house dust mite (HDM), the major cause of allergy in the Western world.

S-TARget therapeutics was founded by two experienced, senior pharma professionals with top-level research & development and management backgrounds.
The privately held company is based in Vienna/Austria

For more information see our corporate presentation:

S-TARget therapeutics Corporate Presentation